Answers are grounded in this paper and cite their sources.
Inotuzumab ozogamicin achieves high response and molecular remission rates in patients with relapsed/refractory acute lymphoblastic leukemia with tolerable toxicity. It warrants further studies of inotuzumab in combination with chemotherapy or other targeted therapy.
No takes yet. Share an insight, caveat, or question.
Dieter Hoelzer (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: